相关实验视频

Updated: Mar 3, 2026

High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease

High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease

Published on: October 31, 2012

在患有严重狼性炎的儿科患者中,成功地将瑞图西马布与血交换结合到瑞图西马布

Taro Yoshida¹, Hiroshi Sugahara², Keisuke Oikawa³

¹Pediatrics, Iwate Medical University, Morioka, JPN.

|March 2, 2026

概括

早期血交换 (PE) 与免疫抑制剂相结合,有效地治疗了14岁女孩的重症儿科狼性炎 (LN),导致完全缓解,并使类固醇停用.

科学领域:

腎臟病學 (nephrology) 是一種醫學專業.
免疫学免疫学免疫学
儿科儿科儿科

背景情况:

严重的儿科狼性炎 (LN) 带来了重大管理挑战.
类IV-G (A) LN可以表现为性综合征,急性损伤和高血症.
积极的免疫抑制对于管理严重的LN至关重要.

研究的目的:

报告一名患有IV-G (A) 类严重狼性炎的儿科患者的成功治疗策略.
评估早期血交换 (PE) 与多模式免疫抑制相关的作用.
突出个性化治疗方法的长期结果.

主要方法:

开始甲基普雷迪尼索隆脉冲疗法,然后进行早期血交换 (PE).
组合免疫抑制疗法包括mycophenolate mofetil,rituximab,tacrolimus,基诺和贝利马布.
用抗凝药治疗并发症的管理,包括深静脉血栓和肺栓塞.

主要成果:

在PE后,功能逐渐改善,自身抗体水平显著降低.
在18个月内实现完全缓解,血清和尿路标志物正常化.
成功停止皮质类固醇治疗和持续控制疾病.

结论:

早期的血交换 (PE) 可能有助于在重症儿科狼性炎 (LN) 中有效的利图西马布治疗.
个性化,多模式治疗策略对于优化高风险儿科LN患者的治疗结果至关重要.
组合疗法包括贝利穆马布在类固醇减量和长期疾病管理中的辅助药物.

关键词:

急性脏损伤急性脏损伤在 sle 中进行免疫抑制疗法.狼性炎是一种神经炎症.儿科儿科儿科血交换疗法是一种血交换疗法.这就是Rituximab.类固醇-节省使用.

更多相关视频

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line

Published on: May 10, 2017

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

相关概念视频

Pharmacokinetics in Pediatric Patients: Drug Excretion

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in...

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...